Cannabinoid-containing plant extracts as neuroprotective agents
US-9205063-B2 · Dec 8, 2015 · US
Cannabinoids for use in the treatment of neurodegenerative diseases or disorders
US10258580B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10258580-B2 |
| Application number | US-201214128208-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2012 |
| Priority date | Jul 1, 2011 |
| Publication date | Apr 16, 2019 |
| Grant date | Apr 16, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for treating neurodegenerative diseases or disorders comprising administering to a subject in need thereof a therapeutically effective amount of cannabinoids cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA), wherein the CBDV and/or CBDVA are isolated or purified. 2. The method of claim 1 , wherein the cannabinoid is CBDV. 3. The method of claim 1 , wherein the cannabinoid is CBDVA. 4. The method of claim 1 , wherein the neurodegenerative disease or disorder is selected from the group consisting of: Alzheimer's disease; Parkinson's disease; amyotrophic lateral sclerosis; and Huntington's disease. 5. The method of claim 4 , wherein the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease. 6. The method of claim 1 , wherein the cannabinoid/s are administered in a daily dose effective to prevent or treat neurodegenerative diseases or disorders. 7. The method of claim 6 , wherein the effective daily dose of cannabinoid/s is between 5 mg and 1000 mg. 8. The method of claim 7 , wherein the effective daily dose of cannabinoid/s is between 10 mg and 50 mg. 9. The method of claim 1 , further comprising administering the cannabinoid/s in combination with one or more other medicinal substances. 10. The method of claim 1 , wherein the cannabinoid/s are in the form of a botanical drug substance (BDS).
Assignees
Inventors
Classifications
for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Anti-Parkinson drugs · CPC title
Drugs for disorders of the nervous system · CPC title
- A61K36/185Primary
Magnoliopsida (dicotyledons) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10258580B2 cover?
- The present invention relates to cannabinoids for use in the prevention or treatment of neurodegenerative diseases or disorders. Preferably the cannabinoids are cannabichromene (CBC) cannabidivarin (CBDV) and/or cannabidivarin acid (CBDVA). More preferably the neurodegenerative disease or disorder to be prevented or treated is Alzheimer's disease.
- Who is the assignee on this patent?
- Iuvone Teresa, Di Marzo Vincenzo, Guy Geoffrey, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K36/185. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).